Rationale: Nitric oxide formation is deficient in airways of patients with cystic fibrosis (CF). Since nitric oxide has bronchodilatory effects, nitric oxide deficiency may contribute to airway obstruction in CF. Objectives: We reasoned that inhalation of L-arginine, the precursor of enzymatic nitric oxide formation, could improve airway nitric oxide formation and pulmonary function in patients with CF. Measurements: Exhaled nitric oxide, pulmonary function, and peripheral oxygen saturation were measured before and after a single inhalation of nebulized L-arginine solution in patients with CF and in healthy subjects. A saline solution of similar osmolarity (1.7%) was used as control. Results: Nebulized L-arginine not only significantly increased exhaled nitric oxide concentrations but also resulted in a sustained improvement of FEV 1 in patients with CF. Oxygen saturation also increased significantly after the inhalation of L-arginine. Nebulized saline resulted in a small but significant increase in exhaled nitric oxide but a decrease in FEV 1 in patients with CF. In control subjects inhalation of L-arginine increased exhaled nitric oxide concentrations, but FEV 1 decreased. No effect of saline on exhaled nitric oxide, pulmonary function, or oxygen saturation was observed in healthy subjects. Conclusions: These data suggest that a single inhalation of L-arginine acutely and transiently improves pulmonary function in CF through the formation of nitric oxide. Augmentation of airway nitric oxide formation by inhalation of L-arginine is a promising therapeutic approach in patients with CF.
Animal experiments have shown that airway relaxation is significantly impaired in cftrϪ/Ϫ mice and that this relaxation defect in CF airways can be reversed by an improvement of enzymatic NO formation through the addition of the NOS substrate l-arginine (13) . These data suggest that NO deficiency results in airway obstruction in patients with CF and may be improved by increasing l-arginine concentrations in the airways. Previous clinical studies in patients with CF had shown that Fe NO could be increased by l-arginine given either orally or intravenously but had failed to demonstrate an effect on pulmonary function (14, 15) . This lack of effect may be due to ineffective augmentation of l-arginine concentrations in CF airways. Since high doses of l-arginine can be delivered to the airways by inhalation, we here performed a pilot study to assess the effect of nebulized l-arginine solution on Fe NO and lung function in patients with CF. Some of the results of these studies have been previously reported in the form of abstracts (16, 17) .
METHODS

Study Cohort
Thirteen patients with CF (7 females) aged 14 to 45 yr (mean Ϯ SD; 20.1 Ϯ 9.1 yr) were studied. Mean FVC at baseline was 66 Ϯ 25% (range, 35-120%) and mean FEV 1 was 47 Ϯ 21% (range, 24-95%) of predicted values. The diagnosis of CF in participating patients had been confirmed by repeated sweat tests with chloride concentrations exceeding 60 mmol/L and by mutation analysis of the CFTR gene. All patients were chronically infected with Pseudomonas aeruginosa; five were co-colonized with Staphylococcus aureus. None of the patients received systemic or inhaled corticosteroids at the time of study. All patients were included in clinically stable condition. Exclusion criteria were allergic bronchopulmonary aspergillosis, Burkholdia cepacia infection, or an additional diagnosis of asthma. Patients were compared with nine (4 females) nonsmoking, healthy control subjects 22 to 28 yr (25.1 Ϯ 1.3 yr) of age. The study was approved by the ethics committee of the University of Duisburg-Essen. Written informed consent was obtained by all patients and/or their parents as well as by all control subjects.
Study Protocol
The study medications consisted of 18 ml of a 7% l-arginine hydrochloride solution (600 mOsmol/kg, pH 5-6) containing 1.3 g of l-arginine or 18 ml of 1.7% saline (NaCl) with similar osmolarity and pH as a control. The l-arginine solution was prepared by diluting with sterile water a 21% (wt/vol) l-arginine hydrochloride solution that is licensed for intravenous use (Braun Melsungen AG, Melsungen, Germany). Osmolarity was measured by cryoscopy. The study medications were administered in the morning 15 min after pretreatment with two puffs albuterol. The solutions were nebulized via a customized PARI eFlow electronic nebulizer from pilot series 03 (PARI, Starnberg, Germany) on two separate days in random order with at least 72 h between the two inhalations. The study medication was blinded to the participants. No additional albuterol or other bronchodilatory drug was given within 6 h after the nebulized solutions, or 8 h before study end (24 h ). Pulmonary function (bell-spirometer, Volugraph; Mijnhardt, Bunnik, The Netherlands), Fe NO , and peripheral oxygen saturation were recorded at baseline, immediately after inhalation, once every hour for 6 h, and after 24 h. Blood was collected in EDTA-containing 2.7-ml tubes by venipuncture at the same time points. Spontaneously expectorated sputum was collected at baseline, after 4 h, and after 24 h.
Measurements of FE NO
Single-breath online measurements for the assessment of lower airway NO were performed at a constant expiratory flow of 50 ml ϫ min Ϫ1 (FeNO 50 ), in accordance with published ERS/ATS standards (18, 19) . A chemiluminescence analyzer (NOA 280; Sievers, Boulder, CO), that was calibrated before each study with 0 and 185-ppb NO calibration gas (Linde AG, Unterschleissheim, Germany) was used to measure Fe NO . The mean value of three end-expiratory NO concentrations within a variation of 15% was calculated for each subject.
Amino Acid Measurements
Plasma and sputum samples were deproteinized within 30 min after collection. Amino acids were determined by ion exchange chromatography (LC 3000; Eppendorf, Hamburg, Germany). Sputum samples were diluted with buffer 1:1 and vortexed for 2 min, followed by 10 min of centrifugation at 1,000 ϫ g for 10 min. Clear supernatant was used for chromatography.
Statistics
Data are shown as means Ϯ SEM. Comparisons of time courses of Fe NO , pulmonary function, oxygen saturation, and amino acid concentrations within groups were done by repeated-measure one-way ANOVA.
RESULTS
Inhalation of l-arginine and saline was well tolerated by all patients and control subjects. In patients with CF l-arginine resulted in a significant increase of Fe NO after inhalation (p Ͻ 0.0001, ANOVA). Fe NO had returned to baseline values after 24 h ( Figure 1A ). Mean FEV 1 increased significantly 4 h after l-arginine inhalation (p Ͻ 0.0005). Similarly, FEV 1 in % of baseline increased significantly (p ϭ 0.03) (Figure 2A ). No significant changes in FVC were seen (data not shown). Inhalation of saline in patients with CF resulted in a smaller but statistically significant (p Ͻ 0.05) increase of Fe NO ( Figure 1A) . In contrast to l-arginine, a significant decrease in FEV 1 (p ϭ 0.004) was seen immediately after the inhalation of saline that returned to baseline thereafter (Figure 2A) . No significant changes in FVC or oxygen saturation were observed after the inhalation of saline. Mean peripheral oxygen saturation improved by approximately 1% immediately after l-arginine inhalation in patients with CF (p ϭ 0.001) (data not shown).
In healthy subjects inhalation of l-arginine solution, but not saline, led to an increase in Fe NO (p Ͻ 0.0001, ANOVA) ( Figure  1B) . In contrast to CF, inhalation of l-arginine was followed by a small but statistically significant reduction in FEV 1 (p Ͻ 0.001) ( Figure 2B ). No effect of saline inhalation on pulmonary function was observed in the control subjects. Neither l-arginine nor saline inhalation resulted in significant changes of oxygen saturations in control subjects (data not shown).
Sputum amino acid concentrations after the inhalation of nebulized l-arginine are shown in Figure 3 . l-arginine concentrations increased significantly (p Ͻ 0.0001) after inhalation and had returned to baseline after 24 h. The increases in sputum l-citrulline and l-ornithine concentrations were not statistically significant ( Figure 3 ).
Plasma amino acid concentrations after the inhalation of nebulized l-arginine are shown in Table 1 . The concentrations of l-arginine and l-citrulline, the product of l-arginine conversion by NOSs, did not change significantly over time. However, the concentrations of l-ornithine, the product of l-arginine conversion by arginase, significantly increased (p Ͻ 0.001), but had returned to baseline after 24 h.
DISCUSSION
This is the first controlled study showing that l-arginine supplementation in patients with CF not only increases Fe NO but also improves pulmonary function. Our data confirm previous findings of reduced NO formation in CF and also provide evidence that improvement of NO deficiency has a positive effect on lung function in patients with CF. An increase in Fe NO after supplementation of l-arginine in patients with CF had been shown previously for single doses of l-arginine given intravenously (500 mg/kg body weight) or orally (200 mg/kg body weight). These regimens, however, had no effects on pulmonary function (16, 17) . A 6-wk trial of oral l-arginine supplementation (200 mg/kg body weight three times daily) versus placebo also showed no effect on pulmonary function (17) . Similar to results from the previous studies, Fe NO did not normalize after l-arginine supplementation; however, increases in Fe NO in the previous studies were less pronounced than after the inhalation of l-arginine. This can be explained by differences of l-arginine distribution in the compartments after different routes of l-arginine supplementation with higher l-arginine levels being achieved in the lungs after inhalation.
Improvements in Fe NO and oxygen saturation in patients with CF occurred early after the inhalation of l-arginine, while the most apparent increase in FEV 1 was seen after 4 h. However, in contrast to saline, there was no initial decrease in FEV 1 after the inhalation of l-arginine in patients with CF. This may reflect a protective effect of NO on airway constriction, as previously demonstrated for airway hyperresponsiveness in patients with asthma (20) . In addition, these different time courses may also suggest that some effects of increased airway NO formation may not be mediated by NO itself but through formation of biologically active metabolites.
Studies in patients with asthma had shown that S-nitrosothiols (SNOs), which are formed by protein S-nitrosylation, act as natural bronchodilators, and that depletion of SNOs may aggravate airway obstruction (21) (22) (23) . We have previously demonstrated that SNOs are decreased in CF airway fluids even in patients with mild lung disease in whom stable NO metabolites were within normal range (12) . Inhalation of S-nitrosoglutathione (GSNO) improved oxygenation in patients with CF in a pilot study (24) . Whether this effect could be directly attributed to SNOs or to restoration of depleted glutathione (GSH) stores in CF airways is unclear; however, glutathione inhalation alone, as well as the inhalation of NO containing gas in concentrations of 100 ppb to 40 ppm, had no immediate effect on lung function or oxygenation (25, 26) . It is therefore possible that some of the effect of inhaled l-arginine on airway diameter and oxygen saturation observed was mediated through the formation of NO metabolites such as SNOs. In fact, recent data suggest that most actions of NOSs are not mediated by NO itself but by protein S-nitrosylation (27) . Alternatively, positive effects of increased l-arginine levels in the airways on pulmonary function and oxygen saturation could also reflect mucolytic activities of the amino acid, as suggested by the authors of a preliminary study on inhaled l-arginine in patients with CF that was performed at a time before the role of arginine as substrate for the formation of NO was known (28) . However, these initial studies have not been confirmed, and mucolytic activity of l-arginine was later found to be rather limited (29) . The observation that Fe NO and FEV 1 significantly outlasted the increase in l-arginine concentrations in sputum may be explained by either conversion of l-arginine to NO-storing metabolites that are both bioactive and capable of releasing NO over time, or a transport of the inhaled l-arginine from the airway surface to a different compartment, for instance to intracellular sources. Therefore, the level of l-arginine in cells or tissues responsible for NO formation and smooth muscle relaxation may not be adequately reflected in airway secretions.
There is increasing evidence for a functional relevance of low NO concentrations in CF. A positive correlation between Fe NO and pulmonary function has been observed repeatedly (8, 11, 30, 31) . In addition, it was recently reported that neuronal NOS gene (NOS1) variants that are associated with low Fe NO predispose to a more rapid decline in pulmonary function in children with CF (32) . Genetic variants in the NOS1 and NOS3 genes that lead to low Fe NO were also found to be associated with an increased rate of colonisation of CF airways with P. aeruginosa (33, 34) . These studies support the concept that NO augmentation may have beneficial effects in patients with CF.
However, NO augmentation may also have detrimental effects in CF: Excessive NO formation from upregulated NOS2 in asthma is believed to aggravate airway inflammation (7, 35) . Decreased expression of NOS2 and subsequently reduced airway NO formation in CF may thus protect the CF airways from NOmediated damage, a mechanism that could be counteracted by increasing the substrate for NO formation. In addition, high amino acid concentrations in airways may promote growth of auxotrophic P. aeruginosa in CF (36, 37) , and, since Pseudomonas can use arginine as substrate, delivery of l-arginine into CF airways may have a positive effect on Pseudomonas growth. However, there is also evidence that augmentation of airway NO formation has an inhibitory effect on bacterial growth. This is supported by the observation that the NO donor sodium nitroprusside induced a dose-dependent killing of P. aeruginosa in vitro in high concentrations (9) . So far, there is insufficient in vivo evidence that NO concentrations adequate to promote bacterial killing can be achieved with NO augmentation therapy, but this will need to be studied in subsequent trials of l-arginine inhalation in CF. Based on the observation that l-arginine in sputum had returned to baseline values 24 h after the inhalation, it appears that the amino acid does not accumulate in the airways. Further trials are needed to study dose response and kinetics of arginine metabolism in CF airways after repeated inhalations.
The mechanisms resulting in reduced expression of NOS2 in CF airways are currently unknown, but seem to be related to inflammation (38) and may involve altered transforming growth factor (TGF)-␤1 signaling (39) . Of interest, the expression of NOS2 is also inhibited in conditions with reduced arginine availability (40) (41) (42) (43) , and there may be multiple mechanisms by which l-arginine affects NOS2 expression, such as control of NOS protein stability or induction of NOS2 mRNA, as recently reviewed (44) . One factor that may reduce the availability of l-arginine for NO synthesis in CF is the expression of arginase, an enzyme that competes with NOSs for the common substrate l-arginine (45). Arginase activity was recently found to be increased in CF sputum (46) . The increase in l-ornithine plasma levels after l-arginine inhalation most likely reflects arginase activity, since l-ornithine is the product of l-arginine conversion by arginase. As specific arginase inhibitors become available, they could potentially be useful to enhance the effect of l-arginine supplementation therapy in patients with CF.
In conclusion, our preliminary observations suggest that a single inhalation of l-arginine results in an acute and transient improvement of pulmonary function and oxygenation in patients with CF. These promising data will stimulate larger trials assessing the efficacy of increased l-arginine availability in airways on nitric oxide formation, lung function, P. aeruginosa growth, and inflammation in patients with CF. 
